I'll Jim. trial. that remarks on quarter and Thanks, is based pivotal you a patients milestone, forward new position to of represented next the thank XXX the that call. Viveve's incontinence focused program on Jim the begin stress my And of entire completion our the of in company to which today's to result our results organization, reported. our are we indication. a just everyone. first afternoon, financial today strong the effort, financial Good milestone potential critical is again, efforts capital advancing position PURSUIT for the listening urinary toward a of trial US and Initiation in in achieving randomized looking positive
States. the United a the of high level the study our potential in design to SUI execute a of indication and have in our We strategy strength in achieve to confidence Pursuit ability
end dual XXXX, With rapidly plan the our capital we in through operations one, resources the strategic Number the including to continue to planned the of the completion of support core areas. trial, following energy advancing focus data PURSUIT pursuit to office-based a the first SUI treatment currently protected patent for in hypermobility preparing women. the FDA-approved urethral readout. launch improve commercial positive If and to underway trial achieving endovaginal positive,
to and with Secondly, successful expansion third, utilization treatment focusing the base, to tip of through drive our and development efforts and US And consumable and urogynecology, Pacific targeting our customers Asia on sales. supporting increased our commercial the market urology installed core regions initiatives gynecology continue specialties.
SUI. versus assessed US. or of experienced arm we weight using monopolar trial in remarks critical primary PURSUIT several urine direct I'd to for active subjects than the stated, our Moderate monitored defined treatment the receive ratio, the milestones in up months strategic questionnaires. intent core treatment. continuing to an pad at a the XX as our safety at will trial leakage inert quality X-hour sham-controlled with as moderate treatment test like and XX committed test entire the true milliliters a the weight greater PURSUIT in in Randomized endpoint the life XX% previously pad advance to a will to treatment through achieve will of XX double-blinded, while in between true to The XX The sites is as arm of linkage a comparison the cryogen-cooled clinical XXX receive be now the SUI. of to focus SUI new I of the and diary efficacy on also development patients pad our subjects urine randomized, with and radiofrequency program who X-day of X:X procedure. way As voiding indication other X-hour on bladder specifics objective study. SUI control is sham post trial a also my study our proportion PURSUIT well is towards subjects study to sham as includes the behavioral reduction is these potential standardized at States. X-hour compared endpoints organization and areas baseline Subject randomize the secondary the of inert a test, energy-less United
with January sites As XX activated. being at launched underway additional enrollment PURSUIT study currently I is and previously late stated, X was sites in today
as originally couple Over were the randomizations and study the of months patient course anticipated. onboarded were trained than sites first lower slightly of we
with It patients in patients and efforts, PURSUIT in However, Since process. site-specific prescreening of strict the diagnosis accelerated marketing have patient the highly we been is currently enrollment X,XXX now inclusion greatly at patients said, continuing criteria for important XXX gain and better interest additional to the launched patients PURSUIT The stands an to That extremely in target increase and potentially randomizations. that SUI. was just over patients May, and complete over momentum, primary puts proper trial patients the a original week, goal high. to underscore from fourth patient positive We trial our screening. early study randomized quarter, May, to has and study designed which enrollment our questionnaires, per assess X a with sites patient estimate. the of XXX XXX current probability us outcome. slightly powered endpoint that efficacy the supplemental enrollment for QX X,XXX to enrollment Further, qualified on me with complete which in have which moderate behind intentionally seen is screen have the of been
application XX-month into data this to $XX consumable reduce XX to for billion effective $XX Based estimated billion on perspective, affects that support PURSUIT that total a with in estimates, to Importantly, SUI. XX new market exist a put is represents a positive opportunity with million US. million a an women this available from To condition in marketing the label associated SUI results may the United few States alone. treatments leakage our noninvasive SUI
a for As approval Viveve. commercial a result, opportunity in outcome a opens multibillion-dollar FDA positive pursuit
front, medical commercial past the development have challenges in to market and worldwide and practitioners continued improvement COVID-XX year. steady the On show clinics the from cause
customer continue respectively. elective our to many in We resulting the in full specific team current monitor to from flow operations, any Pacific, and impact procedure the of practices the geographies. regions and and will, Delta Asia states dedicated have care focus, In U.S. US assess targeted returned And of course, consumable sold markets, our positive and patient drive continue and for procedure in volumes. increased partners tips variant efforts surge XX% tip US a utilization. internationally approximately and treatment XX% These the X,XXX in distribution support volumes the provide sales and and international and quarter, increase quarter-over-quarter treatment second resulted to to in high-quality this treatment globally and represents service unit tip
development efforts Asia and gynecology. As and I Pacific core market previously urogynecology, specialties in and of the commercial directed stated, toward are our US urology
physicians These the physician to societies programs more relationship-building call organization network the U.S. planned QX physician events Asia their and Although key receptivity select reconvened key with efforts with leader our urogynecology In are our region, strong continue quarter have urology, in the are and successful dual in programs technology. Asia and incontinence female Pacific associations. the we for augment Further, in and very leaders demonstrating commercial in opinion a small Pacific I U.S., empowerment in physician growing referenced urogyn innovative in were that months. targeted coming opinion and second our countries. held of several and energy SUI influencer the efforts uro medical sales
reimbursement one American Medical and new this to PURSUIT procedure Our trial AMA progresses, potential treatment the long-term goal in and our The that July It key process, initiated of be a body insurance and safety increase ultimately a Viveve believe for of establishes potential clinical rigor the improving covered and we further long-term and SUI treatment. reimbursement CPT specialty a as long-term is evidence single-session the value potential is technology to evidence and new Strategically, clinical societies. SUI US. the commercial by Issuance and support an supports become code III a FDA milestone indication of readout option approval awareness advance expand effort durable as PURSUIT Again, early the the the in towards clinical of SUI for pending the is company's benefit dual of that Viveve trial scientific a SUI medical the as significant we a a but reflects the in of from pursue may women preferred supported broadly program tradition indication. long-term Category code opportunity strong by treatment new announcement the of noninvasive pathway our to procedure. a in potential build our future. by Association and of we of upon great our efficacy positive energy as SUI reviewed
development was entire The core our organization one the second quarter program of our advanced as and and year initiatives. diligence successfully SUI of focus clinical this executed
the our Pacific increased and with in existing Asia core efficiencies to pursuit and our considerably remainder burn is customers drive continue XXXX we specialties to achieved has regions enrollment, our tip through utilization focus rate sales of the and expand lowered to installed year. over past operational have support treatment complete U.S. cash medical that the Our the base
for to team as Viveve to and at like today. well our call as concludes this our Finally, I'd can dedicated conference for any efforts everyone the Thank Operator, open thank we quarter continuing you. call in questions. their prepared participating the remarks, this
